Thursday, August 19, 2021 4:14:57 PM
What would a buyout be valued at?
Lots of opinions but here's a real life example to use as a comparison.
https://www.newcannabisventures.com/village-farms-enters-u-s-cbd-market-with-75-million-acquisition/
I can't find 2020 sales for cbdistillery but they expect 30m in 2022, and I saw an estimate of $20m in 2020. So I think it's fair to say they are similar or slightly higher in revenue to CVSI. However they look more asset heavy for better or worse.
Their DTC looks much better. In fact I'd say hands down it's superior.
Paying $75m for what is expected to be $30m annual revenue puts some reality into what the CVSI supplements division is worth.
If we use this percentage on CVSI, assuming $25m revs in 2022, and I expect they will use the full $10m available by selling shares, they could sell for $62.5M and have roughly 125-130m shares outstanding. This works out to about 50 cents a share depending on how many they sell to keep afloat.
Honestly seeing this sale is kind of depressing but I think it puts in perspective the competitive landscape.
Lots of opinions but here's a real life example to use as a comparison.
https://www.newcannabisventures.com/village-farms-enters-u-s-cbd-market-with-75-million-acquisition/
I can't find 2020 sales for cbdistillery but they expect 30m in 2022, and I saw an estimate of $20m in 2020. So I think it's fair to say they are similar or slightly higher in revenue to CVSI. However they look more asset heavy for better or worse.
Their DTC looks much better. In fact I'd say hands down it's superior.
Paying $75m for what is expected to be $30m annual revenue puts some reality into what the CVSI supplements division is worth.
If we use this percentage on CVSI, assuming $25m revs in 2022, and I expect they will use the full $10m available by selling shares, they could sell for $62.5M and have roughly 125-130m shares outstanding. This works out to about 50 cents a share depending on how many they sell to keep afloat.
Honestly seeing this sale is kind of depressing but I think it puts in perspective the competitive landscape.
Recent CVSI News
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 03/26/2026 09:14:16 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/26/2026 08:06:03 PM
- CV Sciences, Inc. Reports Fiscal Year-End 2025 Financial Results • ACCESS Newswire • 03/26/2026 08:00:00 PM
- CV Sciences, Inc. To Announce Year End and Fourth Quarter 2025 Results On March 26, 2026 • ACCESS Newswire • 03/24/2026 09:00:00 PM
- CV Sciences Announces Successful Debt Restructuring Designed to Strengthen Financial Position and Fuel Future Growth • ACCESS Newswire • 03/10/2026 09:00:00 PM
- CV Sciences Launches EMPOWR: A Plant-Based Protein + Creatine Formula Designed for Total Wellness • ACCESS Newswire • 02/26/2026 01:30:00 PM
- CV Sciences, Inc. Positioned to Participate in the Medicare and Medicaid Pilot Program for CBD • ACCESS Newswire • 12/23/2025 12:00:00 AM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/13/2025 10:19:06 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/13/2025 09:04:08 PM
- CV Sciences, Inc. Reports Third Quarter 2025 Financial Results • ACCESS Newswire • 11/13/2025 09:00:00 PM
- CV Sciences, Inc. to Announce Third Quarter 2025 Results on November 13, 2025 • ACCESS Newswire • 11/10/2025 11:15:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/10/2025 09:05:25 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/18/2025 08:24:23 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/13/2025 09:23:14 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/13/2025 08:01:09 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/14/2025 08:50:18 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/14/2025 08:01:33 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 04/15/2025 09:25:41 PM
